Final answer:
For a patient with ALL receiving imatinib, daily weight monitoring should be specified in the nursing care plan to track potential fluid retention associated with the treatment. The Correct Answer is Option. A.
Step-by-step explanation:
When planning the care of a patient with acute lymphoblastic leukemia (ALL) who is receiving imatinib, it is essential to undertake specific assessments that are most relevant to the patient's condition and treatment. One of the important assessments to specify in the patient's plan of nursing care would be daily weights.
Daily weight monitoring is crucial as it can indicate changes in the patient's fluid status, which can be affected by the disease and its treatment. Additionally, imatinib may have adverse effects that include fluid retention, requiring close monitoring of the patient's weight for any signs of this condition.
An assessment of deep tendon reflexes could be relevant if neurological complications are suspected, but they are not specific to imatinib. Bilateral blood pressures are not routinely measured unless there is a specific indication such as suspected vascular abnormalities. Similarly, while pupillary response may be a standard neurological assessment, it is not specifically tailored to the patient's treatment with imatinib unless neurological issues are suspected as part of clinical manifestations.